ROCKET PHARMACEUTICALS, INC.

Rocket Pharmaceuticals (RCKT) shows zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating no immediate governance disruptions in our monitoring window. However, a short observation period captures only a snapshot of risk—the full $49 Report extends analysis back 12 months, applies our proprietary dilution risk scoring, and contextualizes the company's financing history and AI-detected risk signals. For biotech investors, understanding cumulative dilution exposure and historical 8-K patterns is critical to assessing true leverage risk. The full $49 Report adds 12-month 8-K context, dilution scoring, financing trajectory, and structural risk signals unavailable in surface-level filings.